Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Acquisition of CyDex) (Details)

v3.5.0.2
Fair Value Measurements (Acquisition of CyDex) (Details) - Cydex Pharmaceuticals, Inc - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Credit Derivatives [Line Items]    
Amount Of Revenue For Contingent Consideration $ 15.0  
Contingent Consideration Classified as Equity    
Credit Derivatives [Line Items]    
Range of annual revenue subject to revenue sharing $ 23.5 $ 22.5
Revenue volatility 25.00% 25.00%
Average of probability of commercialization 78.00% 73.00%
Sales beta 0.30 0.40
Credit rating BB BB
Equity risk premium 6.00% 6.00%